Keros Therapeutics Inc Stock
Keros Therapeutics Inc Stock price
Key metrics
| Market capitalization | $665.13m |
| Enterprise Value | $153.74m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| EV/Sales (TTM) EV/Sales | 236.52 |
| P/S ratio (TTM) P/S ratio | 1,023.28 |
| P/B ratio (TTM) P/B ratio | 1.21 |
| Revenue growth (TTM) Revenue growth | 8,037.50% |
| Revenue (TTM) Revenue | $650.00k |
Is Keros Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
Keros Therapeutics Inc Stock Analysis
Analyst Opinions
14 Analysts have issued a Keros Therapeutics Inc forecast:
Analyst Opinions
14 Analysts have issued a Keros Therapeutics Inc forecast:
Financial data from Keros Therapeutics Inc
| Sep '24 |
+/-
%
|
||
| Revenue | 0.65 0.65 |
6,400%
6,400%
|
|
| Gross Profit | -0.49 -0.49 |
78%
78%
|
|
| EBITDA | -203 -203 |
27%
27%
|
EBIT (Operating Income) EBIT | -204 -204 |
26%
26%
|
| Net Profit | -182 -182 |
27%
27%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Keros Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Keros Therapeutics Inc Stock News
Company Profile
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.
| Head office | United States |
| CEO | Jasbir Seehra |
| Employees | 136 |
| Founded | 2015 |
| Website | www.kerostx.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
